BioMarin Pharmaceuticals
BMRN
388 hedge funds and large institutions have $16.9B invested in BioMarin Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 150 increasing their positions, 141 reducing their positions, and 52 closing their positions.
25% more call options, than puts
Call options by funds: $249M | Put options by funds: $199M
6% more repeat investments, than reductions
Existing positions increased: 150 | Existing positions reduced: 141
1% more capital invested
Capital invested by funds: $16.8B → $16.9B (+$121M)
4% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 52
1% less funds holding
Funds holding: 393 → 388 (-5)
36% less funds holding in top 10
Funds holding in top 10: 14 → 9 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$182M |
| 2 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$166M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$104M |
| 4 |
Temasek Holdings
Singapore
|
+$92.8M |
| 5 |
Goldman Sachs
New York
|
+$70.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$207M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$99.4M |
| 3 |
AC
Amici Capital
New York
|
-$48.1M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$38.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$36.9M |
BMRN Hedge Fund Activity: Q4 2015 in Review
388 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2015, worth a combined $16.9B — up 0.72% from $16.8B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of BMRN and 50 opened new positions — a net loss of 2 holders — while 141 trimmed existing stakes and 150 added.
The largest buyer was Jennison Associates, adding an estimated $182M. The largest seller was Fidelity Investments, cutting an estimated $207M.
- 388 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2015, down from 393 in Q3 2015.
- Funds reported $16.9B of BioMarin Pharmaceuticals stock for Q4 2015, up 0.72% quarter-over-quarter.
- 50 funds opened new BioMarin Pharmaceuticals positions in Q4 2015 and 52 closed out, a net change of -2 holders.
- The largest BioMarin Pharmaceuticals buyer in Q4 2015 was Jennison Associates, an estimated $182M added.
- The largest BioMarin Pharmaceuticals seller in Q4 2015 was Fidelity Investments, an estimated $207M sold.
Based on aggregated 13F filings for Q4 2015.